Runge H M, Neumann H A, Bauknecht T, Pfleiderer A
Eur J Cancer Clin Oncol. 1986 Jun;22(6):691-6. doi: 10.1016/0277-5379(86)90167-7.
The human tumor colony forming assay was used to evaluate the response of ovarian carcinoma cells from primary tumors, ascitic fluids and metastasis to hormonal treatment. In 12/35 patients a sufficient colony formation (greater than 30 colonies/dish) was obtained in order to perform a simultaneous drug testing. The plating efficiency of the metastatic samples (0.12%) was significantly higher (P less than 0.053) than those from the primary tumor (0.076%) or those that were derived from the ascitic fluid (0.082%). Colonies from the metastatic tissues could be evaluated 2-4 days earlier than those from primary tumors. These discrepancies may be due to a heterogeneity in the clonable tumor cell compartment of primary tumor and metastasis. The antiproliferative properties of the antiestrogen tamoxifen and the progestin gestoneron were studied. In 9/12 cases a significant, dose-dependent reduction of colony formation (greater than 70-90% of the controls) was observed after continuous exposure to 1 mumole tamoxifen. No correlation between the dose response and the content of steroid receptors was found. Even estrogen receptor negative tumor samples showed a maximal antiproliferative effect of tamoxifen.
采用人肿瘤集落形成试验评估原发性肿瘤、腹水及转移灶来源的卵巢癌细胞对激素治疗的反应。35例患者中有12例获得了足够的集落形成(每平皿大于30个集落),以便同时进行药物检测。转移样本的接种效率(0.12%)显著高于原发性肿瘤样本(0.076%)或腹水来源样本(0.082%)(P<0.053)。转移组织的集落比原发性肿瘤的集落可提前2 - 4天进行评估。这些差异可能是由于原发性肿瘤和转移灶中可克隆肿瘤细胞成分的异质性所致。研究了抗雌激素他莫昔芬和孕激素孕诺酮的抗增殖特性。在12例中的9例中,连续暴露于1μmol他莫昔芬后,观察到集落形成显著的剂量依赖性减少(大于对照组的70 - 90%)。未发现剂量反应与类固醇受体含量之间存在相关性。即使是雌激素受体阴性的肿瘤样本也显示出他莫昔芬的最大抗增殖作用。